Steven Cohen’s Beam Therapeutics BEAM Stock Holding History

Steven Cohen’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,900	Closed	-$307K	–	4017
2026 Q1	$307K	Buy	+12,900	New	+$358K	﹤0.01%	3354

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Steven Cohen's BEAM Position: Q1 2025 in Review

Steven Cohen sold out of Beam Therapeutics (BEAM) in Q1 2025, closing a stake of 193,356 shares — an estimated $4.8M sold.

Steven Cohen first reported a position in BEAM in Q2 2020 and held it in 5 quarters. The position peaked at $6.12M in Q3 2020. 238 funds tracked by Wall St. Rank hold BEAM as of Q1 2025.

Steven Cohen reported no remaining Beam Therapeutics position as of Q1 2025 after selling out during the quarter.
Steven Cohen sold 193,356 Beam Therapeutics shares in Q1 2025, an estimated $4.8M.
Steven Cohen first reported a position in Beam Therapeutics in Q2 2020 and held it in 5 quarters.
Steven Cohen's Beam Therapeutics position peaked at $6.12M in Q3 2020.
238 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2025.

Based on Point72 Asset Management's 13F filing for Q1 2025, filed 15 May 2025.